Q: What is Alecensa used for?

Alecensa is used to treat anaplastic lymphoma kinase-positive non-small cell lung cancer .

Q: How does Alecensa work?

Targeting ALK Proteins Alecensa is a type of targeted therapy known as a kinase inhibitor. It is specifically used to treat non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. In this form of cancer, a genetic rearrangement causes the body to produce an abnormal ALK protein. This protein acts as a signal that tells cancer cells to divide and multiply rapidly. Alecensa works by identifying and attaching to these abnormal ALK proteins. By blocking the protein's activity, the medication interferes with the growth signals, which can help to: Slow down or stop the growth of the tumor. Prevent cancer cells from spreading to other parts of the body. Shrink existing tumors. Crossing the Blood-Brain Barrier A key characteristic of Alecensa is its ability to cross the blood-brain barrier. This is a protective membrane that prevents many substances and medications from entering the brain and central nervous system. Because Alecensa can pass through this barrier, it is effective at treating cancer cells that have spread to the brain and may help prevent the development of new tumors in the central nervous system.

Q: What are the active ingredients in Alecensa?

The active ingredient in Alecensa is alectinib .

Q: What are the side effects of Alecensa?

Common side effects of Alecensa may include: Fatigue Constipation Muscle pain and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Alecensa?

Alecensa belongs to the ALK inhibitor drug class.

Q: What is the dosage of Alecensa and how do I take it?

How to Take Alecensa Alecensa is a capsule taken by mouth, usually twice a day. It must be taken with food to ensure the medicine is absorbed correctly. Administration Instructions Swallow the capsules whole. Do not open, crush, chew, or dissolve the capsules before swallowing. Missed Doses and Vomiting If you miss a dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at once to make up for a missed dose. If you vomit after taking a dose of Alecensa, do not take an extra dose. Take your next dose at the scheduled time.

Q: Is Alecensa safe during pregnancy and breastfeeding?

Pregnancy Alecensa may cause fetal harm when administered to a pregnant woman. Animal studies have indicated that the medication can lead to birth defects or pregnancy loss. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this treatment. Contraception Requirements Because of the potential risks to a fetus, healthcare providers recommend using effective birth control during treatment. The specific timelines for contraception include: For women: Use effective birth control during treatment and for at least 1 week after the final dose. For men: Men with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose. Breastfeeding It is currently unknown if Alecensa passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for 1 week after the final dose. Patients should discuss alternative feeding options with their healthcare team.

Q: What forms and strengths does Alecensa come in?

Available Forms Alecensa is supplied as a hard capsule intended for oral administration. It is taken by mouth, typically twice a day with food. Administration Considerations Capsules should be swallowed whole. Do not open, crush, dissolve, or chew the capsules. If a capsule is damaged or broken, avoid touching the powder inside.

Q: What is the FDA approval status of Alecensa?

FDA Approval History Alecensa was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2015. It received full approval in November 2017 for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). Approved Indications The FDA has approved Alecensa for the following uses: Metastatic NSCLC: For the treatment of patients whose lung cancer has spread to other parts of the body and tests positive for the ALK gene mutation. Adjuvant Treatment: In April 2024, the FDA expanded the approval to include use as an adjuvant treatment (treatment after the primary tumor is surgically removed) for patients with ALK-positive NSCLC whose tumors are at least 4 centimeters or whose cancer has spread to the lymph nodes. Regulatory Status and Safety Alecensa is a prescription-only medication. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for this drug. It was granted Breakthrough Therapy Designation and Priority Review during its clinical development for both metastatic and adjuvant settings due to its potential to address unmet medical needs in lung cancer treatment.

Question 1

What is Alecensa?

Accepted Answer

Alecensa is a medication classified as a kinase inhibitor. It works by targeting and blocking the action of an abnormal protein that signals cancer cells to multiply and spread throughout the body.

By inhibiting these specific proteins, the medication helps to slow or stop the progression of the disease. This targeted approach focuses on the underlying mechanisms that allow certain cancer cells to grow.

Question 2

What is Alecensa used for?

Accepted Answer

Alecensa is used to treat anaplastic lymphoma kinase-positive non-small cell lung cancer.

Question 3

How does Alecensa work?

Accepted Answer

Targeting ALK Proteins

Alecensa is a type of targeted therapy known as a kinase inhibitor. It is specifically used to treat non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. In this form of cancer, a genetic rearrangement causes the body to produce an abnormal ALK protein. This protein acts as a signal that tells cancer cells to divide and multiply rapidly.

Alecensa works by identifying and attaching to these abnormal ALK proteins. By blocking the protein's activity, the medication interferes with the growth signals, which can help to:

Slow down or stop the growth of the tumor.
Prevent cancer cells from spreading to other parts of the body.
Shrink existing tumors.

Crossing the Blood-Brain Barrier

A key characteristic of Alecensa is its ability to cross the blood-brain barrier. This is a protective membrane that prevents many substances and medications from entering the brain and central nervous system. Because Alecensa can pass through this barrier, it is effective at treating cancer cells that have spread to the brain and may help prevent the development of new tumors in the central nervous system.

Question 4

What are the active ingredients in Alecensa?

Accepted Answer

The active ingredient in Alecensa is alectinib.

Question 5

What are the side effects of Alecensa?

Accepted Answer

Common side effects of Alecensa may include:

Fatigue
Constipation
Muscle pain
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Alecensa?

Accepted Answer

Alecensa belongs to the ALK inhibitor drug class.

Question 7

What is the dosage of Alecensa and how do I take it?

Accepted Answer

How to Take Alecensa

Alecensa is a capsule taken by mouth, usually twice a day. It must be taken with food to ensure the medicine is absorbed correctly.

Administration Instructions

Swallow the capsules whole.
Do not open, crush, chew, or dissolve the capsules before swallowing.

Missed Doses and Vomiting

If you miss a dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at once to make up for a missed dose.

If you vomit after taking a dose of Alecensa, do not take an extra dose. Take your next dose at the scheduled time.

Question 8

Is Alecensa safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Alecensa may cause fetal harm when administered to a pregnant woman. Animal studies have indicated that the medication can lead to birth defects or pregnancy loss. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this treatment.

Contraception Requirements

Because of the potential risks to a fetus, healthcare providers recommend using effective birth control during treatment. The specific timelines for contraception include:

For women: Use effective birth control during treatment and for at least 1 week after the final dose.
For men: Men with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose.

Breastfeeding

It is currently unknown if Alecensa passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for 1 week after the final dose. Patients should discuss alternative feeding options with their healthcare team.

Question 9

What forms and strengths does Alecensa come in?

Accepted Answer

Available Forms

Alecensa is supplied as a hard capsule intended for oral administration. It is taken by mouth, typically twice a day with food.

Administration Considerations

Capsules should be swallowed whole.
Do not open, crush, dissolve, or chew the capsules.
If a capsule is damaged or broken, avoid touching the powder inside.

Question 10

What is the FDA approval status of Alecensa?

Accepted Answer

FDA Approval History

Alecensa was first granted accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2015. It received full approval in November 2017 for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).

Approved Indications

The FDA has approved Alecensa for the following uses:

Metastatic NSCLC: For the treatment of patients whose lung cancer has spread to other parts of the body and tests positive for the ALK gene mutation.
Adjuvant Treatment: In April 2024, the FDA expanded the approval to include use as an adjuvant treatment (treatment after the primary tumor is surgically removed) for patients with ALK-positive NSCLC whose tumors are at least 4 centimeters or whose cancer has spread to the lymph nodes.

Regulatory Status and Safety

Alecensa is a prescription-only medication. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for this drug. It was granted Breakthrough Therapy Designation and Priority Review during its clinical development for both metastatic and adjuvant settings due to its potential to address unmet medical needs in lung cancer treatment.

Question 11

What should I know about Alecensa and cost?

Accepted Answer

Insurance and Coverage

The out-of-pocket cost for Alecensa is largely determined by your health insurance plan. Most plans require prior authorization for this medication, and your specific co-pay or co-insurance will depend on your plan's specialty drug tier.

Generic Availability

Alecensa is a brand-name medication, and there is currently no generic version of alectinib available. Generic drugs usually cost less than brand-name versions, so the lack of a generic option may contribute to higher costs.

Financial Assistance Programs

The manufacturer may offer support programs to help reduce the cost for eligible patients. These options often include:

Co-pay cards: For patients with commercial insurance to help lower monthly out-of-pocket expenses.
Patient assistance programs: For individuals who are uninsured or underinsured and meet specific income requirements.

Patients should consult with their healthcare provider or a financial counselor at their treatment center to explore available resources.

Alecensa

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Alecensa

Hospitals.net Disclosure